^
    Back
    Association details:
    Biomarker:HER-2 amplification
    Cancer:Gastric Adenocarcinoma
    Drug:Herceptin (trastuzumab) (HER2 inhibitor) +
    Bavencio (avelumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas

    Excerpt:
    ...HER2 amplification confirmed by standard of care testing of tumor specimen (3+ by immunohistochemistry, or 2+ on IHC with ISH with HER2/CEP17 ratio ≥2)....
    Trial ID:
    NCT03783936
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AACR 2021
    Title:

    CT174 - Phase II study of avelumab and trastuzumab with FOLFOX chemotherapy in previously untreated HER2-amplified metastatic gastroesophageal adenocarcinoma

    Published date:
    04/10/2021
    Excerpt:
    HCRN GI17-319 was a multicenter, single-arm, phase II clinical trial with a prespecified 6-subject safety run-in of avelumab, trastuzumab, and mFOLFOX6 in previously untreated, metastatic, HER2-amplified gastric and esophageal adenocarcinomas (NCT03783936)....The 24-week response rate was 11/18 (61%; 95% CI 39-84%), including one complete response. The confirmed overall response rate is 7/18 (39%), but 3 unconfirmed responders are still on treatment.
    Secondary therapy:
    mFOLFOX6
    Trial ID:
    NCT03783936